FROM: U.S. FOOD AND DRUG ADMINISTRATION
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Perjeta was approved in 2012 for the treatment of patients with advanced or late-stage (metastatic) HER2-positive breast cancer. HER2-positive breast cancers have increased amounts of the HER2 protein that contributes to cancer cell growth and survival.
Perjeta’s new use is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (tumor greater than 2 cm in diameter or with positive lymph nodes) who are at high risk of having their cancer return or spread (metastasize) or of dying from the disease. It is to be used in combination with trastuzumab and other chemotherapy prior to surgery and, depending upon the treatment regimen used, may be followed by chemotherapy after surgery. Following surgery, patients should continue to receive trastuzumab to complete one year of treatment.
A PUBLICATION OF RANDOM U.S.GOVERNMENT PRESS RELEASES AND ARTICLES
Search This Blog
Translate
White House.gov Press Office Feed
- President Donald J. Trump's Year of Regulatory Reform and Environmental Protection at the EPA - hliggett
- A Message from President Donald J. Trump on Hanukkah - hliggett
- President Donald J. Trump will Make the American Military Great Again - hliggett
- Statement from President Donald J. Trump Regarding Today's Attack in New York City - hliggett
- F.H. Buckley: "GOP tax bill is good for middle-class Americans" - hliggett